Post-Market Clinical Investigation of the IotaSOFT Insertion System for Use with Cochlear Implant Surgery
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 50
- 试验地点
- 3
- 主要终点
- Number of Subjects Experiencing a Serious or Related Adverse Event Due to Use of the iotaSOFT Insertion System During Cochlear Implant Surgery
研究概览
简要总结
The purpose of the proposed study is to evaluate the continued safety of the iotaSOFT Insertion System when used by a surgeon to assist with inserting a CI electrode array in one ear per subject
详细描述
available iotaSOFT Insertion System when used per intended use for insertion of a cochlear implant electrode array in subjects 12 years and older. The purpose of the study is to collect additional safety data in retrospective and prospective subjects. The primary object of the study is to demonstrate post-market safe use of the commercially available iotaSOFT Insertion System. The secondary objective of the study is to define procedural characteristics including device deficiencies, electrode array insertion speed, rate of tip fold-over, and objective measures of cochlear implant functionality to demonstrate effective use of the commercially available iotaSOFT Insertion System.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 12 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Candidates with sensorineural hearing loss who received or will receive unilateral or bilateral cochlear implantation according to indications for use with FDA approved cochlear implant devices, as listed below:
- •Advanced Bionics HiFocus SlimJ
- •Cochlear Slim Straight
- •MED-EL Flex 24 and 28
- •Age 12 years or older at the time of CI surgery.
- •Willingness to participate in the study and able to comply with the follow-up visit requirements.
排除标准
- •Prior cochlear implantation in the ear to be implanted.
- •Ossification or any other cochlear anomaly that might prevent complete insertion of the electrode array or present an increased risk of aberrant insertion.
- •Craniofacial abnormality, temporal squamosal skull thickness less than 3mm, major cochlear lesions (e.g., fibrosis, fracture, or ossification), or cochlear malformations.
- •Deafness due to lesions of the acoustic nerve or central auditory pathway.
- •Diagnosis of auditory neuropathy.
- •Active middle-ear infection or tympanic membrane perforation in the presence of active middle ear disease.
- •Absence of cochlear development.
- •Additional medical concerns that would prevent participation in evaluations as determined by the investigator.
- •Unrealistic expectations on the part of the subject, regarding the possible benefits, risks, and limitations that are inherent to the procedure and investigational device.
- •Non-native English speakers who are unable to read, understand and/or speak English for completion of required procedures
- •Planned or current participation in a clinical study of an investigational device or drug.
- •Must not fit the definition of a vulnerable subjects, as per FDA regulations 21 CFR Parts 50 and 56
结局指标
主要结局
Number of Subjects Experiencing a Serious or Related Adverse Event Due to Use of the iotaSOFT Insertion System During Cochlear Implant Surgery
时间窗: 1 month post-activation
Number of Subjects Experiencing a Serious or Related Adverse Event Due to Use of the iotaSOFT Insertion System During Cochlear Implant Surgery through 1 month post-operative follow-up
次要结局
- Number of device deficiencies related to the use of the iotaSOFT Insertion System(1 month post-activation)